MEDICAL POLICY- CONTINUOUS GLUCOSE MONITORING

Continuous glucose monitoring is designed as an adjunct to and not a replacement for finger stick measurements. Ideally, measurements via the glucose monitor should be cross-checked with a finger stick measurement prior to insulin adjustments. VCHCP will approve continuous glucose monitoring equipment under the following conditions:

1) Type 1 diabetic -AND
2) Age 8 years or older (based on assessed capability of being trained to use the device in an appropriate manner) -AND
3) Device is approved for use by FDA –AND
4) Under consultation with an endocrinologist or other diabetes specialist -AND
5) The device is ordered through a VCHCP contracted DME vendor -AND
6) Best practices is being followed include a regimen of 3 or more finger sticks each day, adherence to proper diet and exercise as well as dietary and diabetic counseling and monitoring - AND
7) One of the following:
   a) Documented extreme ("brittle") recurrent fluctuations in blood glucose measurements (i.e. symptomatic glucose levels < 50 mg/dL, >300 mg/dL)
   b) Poorly controlled blood glucose levels (unexplained hypoglycemic episodes; recurrent diabetic ketoacidosis) refractory to multiple adjustments in self-monitoring of blood glucose and insulin administration in compliant patients
   c) Frequent hospitalizations for poorly controlled diabetes
   d) Pregnant and incapable of, or poorly compliant in, self-monitoring (including one month post-partum) or are poorly controlled despite best practices (see #6 above)
   e) Documented and clinically significant Hypoglycemic Unawareness after dietary, blood glucose and behavioral adjustments and medical management (e.g. carbohydrate absorption inhibitors)
   f) Frequent nocturnal hypoglycemia despite appropriate modifications in insulin therapy and best practices (see #6 above)
   f) The patient is legally blind and blood glucose levels are poorly controlled despite best practices (special device required)

Patient is to remain on appropriate dosage per treating provider. No authorization is required for supplies refills of continuous glucose monitoring (A9277, A9278, A9276).
Continuous Glucose Monitoring

Effective November 10, 2016

Reviewed/No Updates: 2/9/17, 2/8/18, 2/14/19
Reviewed/Updated: 2/13/20

Attachments: None

Created by Catherine Sanders, MD; Date: November 07, 2016
Committee Review: UM: November 10, 2016; QA: November 22, 2016
Reviewed/No Updates: Catherine Sanders, MD & Robert Sterling, MD
Reviewed/No Updates: Catherine Sanders, MD & Robert Sterling, MD
Committee Review: UM: February 8, 2018; QAC: February 27, 2018
Reviewed/No Updates by: Catherine Sanders, MD & Robert Sterling, MD
Committee Review: UM: February 14, 2019; QAC: February 26, 2019
Reviewed/No Updates by: Howard Taekman, MD & Robert Sterling, MD

<table>
<thead>
<tr>
<th>Revision Date</th>
<th>Content Revised (Yes/No)</th>
<th>Contributors</th>
<th>Review/Revision Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2/9/17</td>
<td>No</td>
<td>Catherine Sanders, MD; Robert Sterling, MD</td>
<td>Annual Review</td>
</tr>
<tr>
<td>2/8/18</td>
<td>No</td>
<td>Catherine Sanders, MD; Robert Sterling, MD</td>
<td>Annual Review</td>
</tr>
<tr>
<td>2/14/19</td>
<td>No</td>
<td>Catherine Sanders, MD; Robert Sterling, MD</td>
<td>Annual Review</td>
</tr>
<tr>
<td>2/13/20</td>
<td>Yes</td>
<td>Howard Taekman, MD</td>
<td>Patient is to remain on appropriate dosage per treating provider. No authorization is required for supplies refills of continuous glucose monitoring (A9277, A9278, A9276).</td>
</tr>
</tbody>
</table>